127 related articles for article (PubMed ID: 35931370)
21.
Chanhom N; Udomsinprasert W; Chaikledkaew U; Mahasirimongkol S; Wattanapokayakit S; Jittikoon J
Biomed Rep; 2020 Apr; 12(4):153-162. PubMed ID: 32190303
[TBL] [Abstract][Full Text] [Related]
22. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Tang N; Deng R; Wang Y; Lin M; Li H; Qiu Y; Hong M; Zhou G
Int J Tuberc Lung Dis; 2013 Jan; 17(1):17-25. PubMed ID: 23232001
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.
Huang YS
J Chin Med Assoc; 2014 Apr; 77(4):169-73. PubMed ID: 24593909
[TBL] [Abstract][Full Text] [Related]
24. Glutamate dehydrogenase combined with ferrochelatase as a biomarker of liver injury induced by antituberculosis drugs.
He B; Cheng X; Xiang HR; Li Y; Zhang QZ; Peng WX; Yang B
Br J Clin Pharmacol; 2023 Oct; 89(10):3092-3104. PubMed ID: 37259680
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection.
Huang YS; Tseng SY; Chen WW; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH
J Chin Med Assoc; 2022 Mar; 85(3):286-294. PubMed ID: 34698694
[TBL] [Abstract][Full Text] [Related]
26. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
27. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
30. Protective Effect of Bicyclol on Anti-Tuberculosis Drug Induced Liver Injury in Rats.
Liu X; Zhao M; Mi J; Chen H; Sheng L; Li Y
Molecules; 2017 Apr; 22(4):. PubMed ID: 28387740
[TBL] [Abstract][Full Text] [Related]
31. The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury.
Zhang J; Zhao Z; Bai H; Jiao L; Wu Q; Wu T; Liu T; Hu X; Song J; Lyv M; Ying B
Evid Based Complement Alternat Med; 2019; 2019():1685128. PubMed ID: 31534460
[TBL] [Abstract][Full Text] [Related]
32. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon.
Enoh JE; Cho FN; Manfo FP; Ako SE; Akum EA
Biomed Res Int; 2020; 2020():9631731. PubMed ID: 32462039
[TBL] [Abstract][Full Text] [Related]
33. Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study.
He L; Gao L; Shi Z; Li Y; Zhu L; Li S; Zhang P; Zheng G; Ren Q; Li Y; Hu B; Feng F
PLoS One; 2015; 10(3):e0119481. PubMed ID: 25798582
[TBL] [Abstract][Full Text] [Related]
34. Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
Qu F; Chen Y; Wang X; He X; Ren T; Huang Q; Zhang J; Liu X; Guo X; Gu J; Xing J
Carcinogenesis; 2015 May; 36(5):543-52. PubMed ID: 25823896
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.
Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M
Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.
Naidoo S; Evans D; Jong E; Mellet K; Berhanu R
S Afr Med J; 2015 Apr; 105(5):393-6. PubMed ID: 26242667
[TBL] [Abstract][Full Text] [Related]
37. Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China.
Wu S; Xia Y; Lv X; Zhang Y; Tang S; Yang Z; Tu D; Deng P; Cheng S; Wang X; Yuan Y; Liu F; Hu D; Zhan S
BMC Public Health; 2012 Jun; 12():454. PubMed ID: 22712786
[TBL] [Abstract][Full Text] [Related]
38. Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy.
Gafar F; Arifin H; Jurnalis YD; Yani FF; Fitria N; Alffenaar JC; Wilffert B
Pediatr Infect Dis J; 2019 Jan; 38(1):50-53. PubMed ID: 30234790
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.
Yimer G; Gry M; Amogne W; Makonnen E; Habtewold A; Petros Z; Aderaye G; Schuppe-Koistinen I; Lindquist L; Aklillu E
PLoS One; 2014; 9(4):e94271. PubMed ID: 24714066
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
